Trial intelligence / Profile preview

VITANI: anifrolumab plus phototherapy versus phototherapy in progressive vitiligo

2024-512041-17-00Phase 2Authorised

Sponsor: Centre Hospitalier Universitaire de Bordeaux
Start: Nov 2023
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Countries: 1

Overview

Phase 2, randomised, double-blind trial in Vitiligo comparing Anifrolumab + phototherapy with Placebo + phototherapy (2 arms). Primary endpoint: Change in Vitiligo Area Scoring Index at week 36. Planned start Nov 2023; status: authorised.

Drugs

anifrolumab

Conditions

Vitiligo

Beyond the preview

Go deeper on 2024-512041-17-00.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2024-512041-17-00.